{"id":12389,"date":"2021-11-04T14:21:30","date_gmt":"2021-11-04T13:21:30","guid":{"rendered":"https:\/\/library.biobridge-event.com\/knowledge\/?post_type=tribe_events&p=12389"},"modified":"2021-11-04T14:21:30","modified_gmt":"2021-11-04T13:21:30","slug":"cellular-matrix-innovation-for-osteoarthritis-management","status":"publish","type":"tribe_events","link":"https:\/\/library.biobridge-event.com\/knowledge\/event\/cellular-matrix-innovation-for-osteoarthritis-management\/","title":{"rendered":"Cellular Matrix innovation for Osteoarthritis management"},"content":{"rendered":"

\n\t\t\t\t\t
\n\t\t\t\t\t\t

Intra-articular injections of PRP offer a holistic approach that may have a simultaneous impact on several etiologic factors of osteoarthritis. The myriad of growth factors and biomolecules in PRP have the potential to disrupt the inflammatory loop associated with osteoarthritis and recover joint homeostasis, which is essential for creating a favorable environment for cartilage regeneration and reducing pain (Chen et al., 2017).<\/span><\/p>\n

PRP for therapeutic use is anticoagulated with citrate-based anticoagulants. This anticoagulation has the advantage of being fully reversible and with no ancillary effect on the patient. PRP coagulation occurs spontaneously at the site of PRP injection. This results in the formation of fibrin clots in which platelets are entrapped and allows the sustained release of growth factors over time (Perez et al., 2014b).<\/span><\/p>\n

The interest for combining the biological effect of PRP with HA viscosupplementation emerged in the last decade. To respond to this interest, Regen Lab developed a new medical device, Cellular Matrix.<\/span><\/p>\n<\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
Our Speaker<\/span><\/h5>\n<\/div>
\"\"<\/span><\/div>
<\/div>
<\/div>
\n
\n

Prof Armin Keshmiri,\u00a0<\/span><\/strong><\/span><\/p>\n

Specialist in Orthopaedics and Trauma Surgery, Chirotherapy (Germany)<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

TOPICS DISCUSSED :<\/strong><\/span><\/p>\n

I) Cellular Matrix innovation for Osteoarthritis management<\/span>
\n(Mr Gomri, Biologist, 5 min)<\/span>
\nA compilation of clinical evidence, cases and testimonies with the use of a standardized PRP-HA combination in OA.<\/strong><\/span><\/p>\n

II) Prof Armin Keshmiri expertise in the use of Cellular Matrix in OA<\/span>
\n(Prof Armin Keshmiri, 25 min)<\/span>
\nA track-record expertise in using Cellular Matrix for OA management.<\/strong><\/span><\/p>\n

III) Q\/A session (15min)<\/span><\/p>\n<\/div>